Industrial Automation Moves into Drug Development

Every medicine comes with a recipe, and the recipe is far longer than most people would guess. Before a drug reaches a pharmacy shelf, its maker has to record exactly how it is produced, how each batch is tested and what counts as acceptable quality. The industry calls this work Chemistry, Manufacturing and Controls, or CMC, and much of it still runs on manual, document-based processes with little standardization. 

That is the problem a new industry group wants to fix. Rockwell Automation, Inc. (NYSE: ROK) announced that it is a founding member of the Digital CMC Consortium, a not-for-profit group building shared digital standards for drug development. The other named founders include Novartis AG (NYSE: NVS, SIX: NOVN.SW), Takeda Pharmaceutical Company Limited (NYSE: TAK, TSE: 4502.T) and Thermo Fisher Scientific Inc. (NYSE: TMO), along with Flagship’s Pioneering Medicines, Stellix, ZS Associates and QbDVision. The group is not brand new. It has already spent a year on joint work and early tests, and is now going public to draw in more of the industry. 

The first target is something called technology transfer. When a drug company hands production to another site, often a contract manufacturer, it has to pass along everything it knows about making the product. Today that usually means a large package of files that the receiving team reads, interprets and enters into its own systems. One industry estimate puts a typical transfer at more than $5 million and from 18 to 30 months, and a 2025 industry roundtable suggested that roughly half of transfers run into quality problems.

The consortium’s idea is simple to describe and hard to do. If both sides agreed on a common digital format, the recipe could move from one company’s software to another’s without being rebuilt each time. Trade coverage of the announcement points to mismatched data formats and processes as a major source of friction. Further out, the group wants to connect the rest of the CMC process, including knowledge management, automated document writing, digital twins and artificial intelligence. 

So why is a company best known for factory controls in the middle of this? Rockwell sells the software and hardware that run production lines, and it already markets its own digital technology transfer product. Getting involved while a drug is still being developed gives it a say in how data is structured long before a plant is built. Its life sciences chief, Matt Weaver, described the aim as linking development, manufacturing and commercialization across a product’s life. A Rockwell report published a week earlier said 90% of life sciences manufacturers now call digital transformation business-critical. 

Rockwell is not the only automation supplier heading this way. Siemens Aktiengesellschaft (OTC: SIEGY, XETRA: SIE.DE) completed its $5.1 billion purchase of Dotmatics, a Boston maker of research software for life sciences, in July 2025. Regulators are moving in the same direction. The U.S. Food and Drug Administration has its own project to develop structured data standards for the quality sections of drug applications. 

There are reasons for caution. The announcement names no published standard, no deadline and no regulator as a participant, although the group says it intends to engage with health authorities. The most striking savings figures also tend to come from companies selling the tools. QbDVision, a founding member, has said large drug developers can cut transfer costs by as much as 50% with digital methods, a figure that comes from the company itself. Standards written partly by suppliers also raise a fair question about whose products will fit them best. 

The real test comes over the next year or two. A first published specification would show the group can turn discussion into something companies can build on. More large drugmakers and rival software suppliers joining would show the standard is meant for the whole industry, and interest from regulators would give it weight. For now, the announcement is best read as a statement of intent from companies that rarely agree on how to share data.